Skip to main content
. 2020 Jun 11;29:100554. doi: 10.1016/j.ijcha.2020.100554

Fig. 1.

Fig. 1

Plasma TMAO (µM) in A– patients with atrial fibrillation (AF) or without AF (non-AF), B – AF patients at different AF progression stages (paroxysmal AF (PAF) with/ without (w/o) low voltage areas (LVA) or persistent AF (persAF), C – AF patients before (baseline) and after AF catheter ablation (follow up).